JP2018506277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506277A5 JP2018506277A5 JP2017539650A JP2017539650A JP2018506277A5 JP 2018506277 A5 JP2018506277 A5 JP 2018506277A5 JP 2017539650 A JP2017539650 A JP 2017539650A JP 2017539650 A JP2017539650 A JP 2017539650A JP 2018506277 A5 JP2018506277 A5 JP 2018506277A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- der
- seq
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108010071690 Prealbumin Proteins 0.000 claims 8
- 102000009190 Transthyretin Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109002P | 2015-01-28 | 2015-01-28 | |
| US62/109,002 | 2015-01-28 | ||
| US201562266556P | 2015-12-11 | 2015-12-11 | |
| US62/266,556 | 2015-12-11 | ||
| PCT/IB2016/050415 WO2016120810A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133642A Division JP7028923B2 (ja) | 2015-01-28 | 2020-08-06 | 抗トランスサイレチン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506277A JP2018506277A (ja) | 2018-03-08 |
| JP2018506277A5 true JP2018506277A5 (enExample) | 2019-03-07 |
| JP6748086B2 JP6748086B2 (ja) | 2020-09-02 |
Family
ID=55299694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539650A Active JP6748086B2 (ja) | 2015-01-28 | 2016-01-28 | 抗トランスサイレチン抗体 |
| JP2020133642A Active JP7028923B2 (ja) | 2015-01-28 | 2020-08-06 | 抗トランスサイレチン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133642A Active JP7028923B2 (ja) | 2015-01-28 | 2020-08-06 | 抗トランスサイレチン抗体 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20160251418A1 (enExample) |
| EP (2) | EP3250592B1 (enExample) |
| JP (2) | JP6748086B2 (enExample) |
| KR (2) | KR102677203B1 (enExample) |
| CN (1) | CN107406499B (enExample) |
| AU (1) | AU2016210888C1 (enExample) |
| CA (1) | CA2974912A1 (enExample) |
| CL (2) | CL2017001924A1 (enExample) |
| CO (1) | CO2017008476A2 (enExample) |
| CU (1) | CU24480B1 (enExample) |
| DK (1) | DK3250592T3 (enExample) |
| EA (1) | EA036080B1 (enExample) |
| ES (1) | ES2934656T3 (enExample) |
| FI (1) | FI3250592T3 (enExample) |
| HR (1) | HRP20221538T1 (enExample) |
| HU (1) | HUE060878T2 (enExample) |
| IL (1) | IL253633B (enExample) |
| LT (1) | LT3250592T (enExample) |
| MX (1) | MX394170B (enExample) |
| PE (1) | PE20180217A1 (enExample) |
| PH (1) | PH12017501318B1 (enExample) |
| PL (1) | PL3250592T3 (enExample) |
| PT (1) | PT3250592T (enExample) |
| RS (1) | RS63906B1 (enExample) |
| SA (1) | SA517382002B1 (enExample) |
| SG (2) | SG10202101763VA (enExample) |
| SI (1) | SI3250592T1 (enExample) |
| TW (2) | TWI786505B (enExample) |
| UA (1) | UA122142C2 (enExample) |
| WO (1) | WO2016120810A1 (enExample) |
| ZA (1) | ZA201705663B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478714A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| SG11202002489YA (en) | 2017-10-06 | 2020-04-29 | Prothena Biosciences Ltd | Anti-transthyretin antibodies |
| KR102581734B1 (ko) * | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
| MA51223A (fr) | 2017-11-29 | 2020-10-07 | Prothena Biosciences Ltd | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
| EP3876713B1 (en) | 2018-11-09 | 2024-10-02 | Neurimmune AG | Patient-derived amyloid xenograft rodent model |
| US20230035402A1 (en) | 2020-03-18 | 2023-02-02 | Al-S Pharma Ag | Misfolded sod1 assay |
| WO2021228987A1 (en) | 2020-05-12 | 2021-11-18 | Neurimmune Ag | Combination therapy for ttr amyloidosis |
| WO2021231982A1 (en) * | 2020-05-14 | 2021-11-18 | City Of Hope | Smc1a antibodies and uses thereof |
| WO2022094152A1 (en) * | 2020-10-28 | 2022-05-05 | Neotope Neuroscience Limited | Anti-transthyretin antibodies and methods of use thereof |
| CN113845593B (zh) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | 抗α-SMA蛋白单克隆抗体、细胞系及其应用 |
| WO2023086989A1 (en) * | 2021-11-12 | 2023-05-19 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| US20240228637A9 (en) * | 2022-10-19 | 2024-07-11 | Ibio, Inc. | Chemokine receptor 8 (ccr8) antibodies |
| TW202434624A (zh) | 2022-11-15 | 2024-09-01 | 瑞士商紐立慕公司 | 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法 |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| JP2026516527A (ja) | 2023-05-19 | 2026-05-25 | ニューリミューン アーゲー | 筋骨格障害及び状態のための新規免疫療法 |
| KR20260113091A (ko) | 2023-11-15 | 2026-07-21 | 뉴리뮨 아게 | 항-트랜스티레틴 항체, 상기 항체를 포함하는 조성물 및 트랜스티레틴-매개 아밀로이드증의 치료 또는 예방 방법 |
| CN122374011A (zh) | 2023-12-15 | 2026-07-10 | 诺和诺德股份有限公司 | 稳定的液体制剂 |
| WO2025238147A1 (en) | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
| WO2026030717A1 (en) * | 2024-08-01 | 2026-02-05 | Profluent Bio Inc. | Systems and methods for protein design |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| WO2007124345A2 (en) | 2006-04-21 | 2007-11-01 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| EP2522730A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| FI20115165A0 (fi) * | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| JP2016514091A (ja) | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| US20160168235A1 (en) * | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| KR102581734B1 (ko) | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
-
2016
- 2016-01-27 TW TW110100085A patent/TWI786505B/zh active
- 2016-01-27 TW TW105102535A patent/TWI718122B/zh active
- 2016-01-28 DK DK16702812.5T patent/DK3250592T3/da active
- 2016-01-28 HU HUE16702812A patent/HUE060878T2/hu unknown
- 2016-01-28 LT LTEPPCT/IB2016/050415T patent/LT3250592T/lt unknown
- 2016-01-28 SG SG10202101763VA patent/SG10202101763VA/en unknown
- 2016-01-28 KR KR1020237037602A patent/KR102677203B1/ko active Active
- 2016-01-28 PE PE2017001287A patent/PE20180217A1/es unknown
- 2016-01-28 UA UAA201708667A patent/UA122142C2/uk unknown
- 2016-01-28 ES ES16702812T patent/ES2934656T3/es active Active
- 2016-01-28 SG SG11201706124VA patent/SG11201706124VA/en unknown
- 2016-01-28 CA CA2974912A patent/CA2974912A1/en active Pending
- 2016-01-28 MX MX2017009806A patent/MX394170B/es unknown
- 2016-01-28 PT PT167028125T patent/PT3250592T/pt unknown
- 2016-01-28 JP JP2017539650A patent/JP6748086B2/ja active Active
- 2016-01-28 HR HRP20221538TT patent/HRP20221538T1/hr unknown
- 2016-01-28 SI SI201631652T patent/SI3250592T1/sl unknown
- 2016-01-28 KR KR1020177023749A patent/KR102598180B1/ko active Active
- 2016-01-28 RS RS20221170A patent/RS63906B1/sr unknown
- 2016-01-28 FI FIEP16702812.5T patent/FI3250592T3/fi active
- 2016-01-28 EA EA201791712A patent/EA036080B1/ru unknown
- 2016-01-28 EP EP16702812.5A patent/EP3250592B1/en active Active
- 2016-01-28 US US15/009,662 patent/US20160251418A1/en not_active Abandoned
- 2016-01-28 CU CU2017000097A patent/CU24480B1/es unknown
- 2016-01-28 WO PCT/IB2016/050415 patent/WO2016120810A1/en not_active Ceased
- 2016-01-28 AU AU2016210888A patent/AU2016210888C1/en active Active
- 2016-01-28 PL PL16702812.5T patent/PL3250592T3/pl unknown
- 2016-01-28 EP EP22195219.5A patent/EP4134379A1/en active Pending
- 2016-01-28 CN CN201680010882.7A patent/CN107406499B/zh active Active
-
2017
- 2017-07-20 PH PH12017501318A patent/PH12017501318B1/en unknown
- 2017-07-24 IL IL253633A patent/IL253633B/en active IP Right Grant
- 2017-07-27 CL CL2017001924A patent/CL2017001924A1/es unknown
- 2017-07-27 SA SA517382002A patent/SA517382002B1/ar unknown
- 2017-08-21 ZA ZA2017/05663A patent/ZA201705663B/en unknown
- 2017-08-22 CO CONC2017/0008476A patent/CO2017008476A2/es unknown
-
2020
- 2020-08-06 JP JP2020133642A patent/JP7028923B2/ja active Active
-
2022
- 2022-11-02 CL CL2022003027A patent/CL2022003027A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510617A5 (enExample) | ||
| JP2018509889A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2021518140A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2019532617A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| JP2019530427A5 (enExample) | ||
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2015520758A5 (enExample) | ||
| JP2014519317A5 (enExample) | ||
| JP2016505546A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2011514150A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JP2022533538A5 (enExample) |